S1300075

Artem20mg+Lumef120mg disp tabs/12/PAC-30


Artemether 20mg + Lumefantrine 120mg fixed dose combination dispersible tablet, blister of 12 tablets. Pakc of 30 blisters.
Indicative Price 17.40 USD

General Description:
Artemether 20mg + Lumefantrine 120mg fixed dose combination dispersible tablet, blister of 12 tablets pack of 30

Technical specifications:
Each dispersible tablet contains Artemether 20mg Ph.Int and Lumefantrine 120mg

Therapeutic class:
Artemether is sesquiterpene lactone derived from Artemisinin.
Lumefantrine is a synthetic racemic fluorene mixture (Dichlorobenzylidine derivative)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations or pack sizes.

Indications:
Treatment of acute uncomplicated malaria caused by P. falciparum alone or with other Plasmodium spp. in areas with significant drug resistance. By Mouth (PO)

Dosage:
Suggested dosing is based on WHO guidelines, please click link below:
http://www.who.int/malaria/publications/atoz/9789241549127/en/

Storage
Do not store above 30 degrees Celcius (86 degrees Fahrenheit);
to be stored in tightly closed original container.
Keep out of reach and sight of children.

Dispensing instructions
Dispense in original container. Do not re-pack

Patients should be advised to disperse each tablet: The dispersible tablet(s) composing 1 dose should be completely dispersed in a small amount of water (approximately 10ml or less). The dispensing device should be rinsed with an additional small amount of water and be given to the patient to ensure full dosage administration.

Lumefantrine absorption is enhanced by co-administration with fat. Patients with acute malaria are often averse to food, therefore, they should be encouraged to resume intake as soon as they can tolerate food to improve absorption. Patients or carers should be advised of the need to take Artemether and Lumefantrine with milk or fat-containing food, particularly on the second (2nd) and third (3rd) day of treatment.

Patients should be advised to repeat dose if vomiting occurs within one hour of taking the last dose.

Guidelines for use
For more details, please see World Health Organisation(WHO),

Guidelines for the treatment of Malaria:

WHO Model List of Essential Medicines:

WHO Model Formulary:
http://apps.wh o.int/medicinedocs/en/d/Js16879e/

http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf

or your regional/national guidelines.

For latest updates check the list of Prequalified Medicines on the WHO website Prequalification Programme.

Component of kits
S9901015 - IEHK2016,kit,basic unit,malaria

Related Products